Metastatic Breast Cancer
Conditions
Keywords
Hormone receptor positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-), Metastatic Breast Cancer (MBC)
Brief summary
The objective of this study is to evaluate the real-world prescription patterns of Palbociclib in breast cancer (BC) patients who were treated with Palbociclib in combination with AI as a 1st line of therapy using the national health insurance claims data in South Korea.
Interventions
DRUGPatients who received Palbociclib as first line therapy in MBC setting
Patients who received Palbociclib as first line therapy in MBC setting
Sponsors
Pfizer
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period * Patients who were diagnosed with BC during the index period
Exclusion criteria
* Male * Prescribed with palbociclib during 12-month period preceding the index date
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total treatment duration and cycle for Palbociclib | From index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the end date of last palbociclib prescription (maximum of 34.8 months from the index date) |
Secondary
| Measure | Time frame |
|---|---|
| Assessment on dose modification of Palbociclib as first line of therapy in BC patients in real-world setting. | From the index date (Index date: 06 Nov 2012 to 30 Sep 2020) to the time of reduction or increase in the dose given in the subsequent Palbociclib prescription (up to 30 Sep 2020) |
Countries
South Korea
Outcome results
None listed